By Colin Kellaher

India's Sun Pharmaceutical Industries Ltd. on Thursday said it agreed to buy Concert Pharmaceuticals Inc. for an initial $576 million in cash.

Mumbai-based drugmaker Sun would pay an initial $8 a share for Concert, a 16% premium to Wednesday's closing price of $6.90 for the Lexington, Mass., late-stage biotechnology company.

Concert shareholders will also receive non-tradeable contingent value rights worth up to an additional $3.50 a share based on milestones tied to the company's deuruxolitinib drug candidate for alopecia areata, a chronic autoimmune skin disease that causes hair loss on the scalp, face or body.

Sun said it expects to complete the acquisition in the first quarter.

Trading in shares of Concert was halted premarket on Thursday.

Write to Colin Kellaher at colin.kellaher@wsj.com

(END) Dow Jones Newswires

January 19, 2023 08:32 ET (13:32 GMT)

Copyright (c) 2023 Dow Jones & Company, Inc.
Concert Pharmaceuticals (NASDAQ:CNCE)
Gráfica de Acción Histórica
De May 2024 a Jun 2024 Haga Click aquí para más Gráficas Concert Pharmaceuticals.
Concert Pharmaceuticals (NASDAQ:CNCE)
Gráfica de Acción Histórica
De Jun 2023 a Jun 2024 Haga Click aquí para más Gráficas Concert Pharmaceuticals.